Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 1,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period B Clear all

Conditions: Healthy
Interventions: Treatment A, Treatment B, Treatment C; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Prostatic Neoplasms, Prostate Cancer
Interventions: CDX1127, SBRT; Biological · Radiation
Lead sponsor: James Larner, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
Interventions: Atezolizumab Injection, Bevacizumab, Transarterial chemoembolization; Drug · Combination Product
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Head and Neck Cancer
Interventions: Pralatrexate With Vitamin B12 and Folic Acid; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Hepatocellular Carcinoma, Hepatitis B, Chronic
Interventions: One time blood draw; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Asthma
Interventions: 84ug MAP0020, 42ug MAP0020, 21ug MAP0020; Drug
Lead sponsor: Allergan; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 2
States / cities: Cypress, California • San Antonio, Texas

Conditions: Multiple Sclerosis
Interventions: Use of functional electrical stimulation for extended duration on the participants' weaker limb; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 22 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Analgesia, Acute Pain, Chronic Pain, Narcotic Abuse, Opioid-related Disorders
Interventions: oxycodone hydrochloride, marketed oxycodone hydrochloride; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
Interventions: Elinzanetant (BAY3427080); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Clear-cell Renal Cell Carcinoma, RCC, Kidney Cancer, Clear-cell Kidney Carcinoma
Interventions: Avelumab, Sunitinib; Drug
Lead sponsor: Guru Sonpavde; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Aggression, Self-Injurious Behavior
Interventions: Functional Communication Training; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 3 Years to 18 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Healthy
Interventions: Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole, Clopidogrel and Omeprazole, Clopidogrel and Esomeprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteers
Interventions: Emraclidine, Itraconazole, Carbamazepine, Metformin; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Interventions: Litifilimab, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 62
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 52 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Cetuximab, Paclitaxel, Carboplatin, Gemcitabine, Cisplatin; Drug
Lead sponsor: Accelerated Community Oncology Research Network; Other
Eligibility: 18 Years and older
Enrollment: 601 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 84
States / cities: Anniston, Alabama • Jonesboro, Arkansas • Anaheim, California + 81 more

Conditions: Healthy Volunteers
Interventions: Scopolamine, TAK-071, Donepezil, Scopolamine Placebo, TAK-071 Placebo, Donepezil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Myeloma, Plasma-Cell, Lymphoma, Malignant
Interventions: Palonosetron, Aprepitant, Dexamethasone; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Systemic Sclerosis
Interventions: MK-2225, Placebo; Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Miami, Florida • Springfield, Missouri

Conditions: Food Effect in Healthy Participants
Interventions: CRS3123 200 mg capsule; Drug
Lead sponsor: Crestone, Inc; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Schizophrenia
Interventions: Elpipodect, Moxifloxacin, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Glendale, California • Orange, California • Hallandale, Florida + 1 more

Conditions: Sunscreening Agents
Interventions: SPF 50 Y65 110 (BAY 987516); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: St. Petersburg, Florida

Conditions: Asthma
Interventions: Fluticasone Propionate MDPI, Fluticasone Propionate/Salmeterol MDPI, Fluticasone propionate/salmeterol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 3
States / cities: Huntington Beach, California • Raleigh, North Carolina • San Antonio, Texas

Conditions: Heart Failure, Congestive
Interventions: GSK2798745 Micronized API without SLS and hypermellose (Tablet A), GSK2798745 Micronized API with SLS and hypermellose (Tablet B), GSK2798745 milled API without SLS and hypermellose (Tablet C); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: morphine sulfate sustained-release capsules, KADIAN; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers

Pilot Study of SBRT and CDX-1127 in Prostate Cancer

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

Biologic Basis of Liver Cancer From Chronic Hepatitis B

Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma

FES: Effect on Walking in the Real World and Participation in Daily Life in People With Multiple Sclerosis.

A Clinical Study To Characterize The Pharmacokinetics And The Effects Of Food On Oxycodone In Healthy Volunteers

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Treatment of Severe Destructive Behavior: FCT Versus Wait-List Control

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC

TAK-071 Scopolamine-Induced Cognitive Impairment Study

Multi-day Doses in Prevention of Nausea and Emesis

A Study of MK-2225 in Healthy Participants (MK-2225-003)

Evaluation of the Potential Impact of a High-fat Meal on the Pharmacokinetics of CRS3123 in Healthy Adult Participants

A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)

To Assess the Safety of a Sunscreen Product

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma

A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets

Comparison of One Morphine Sulfate Sustained-Release 200mg Capsule With Two 100 mg KADIAN Capsules Under Fed Conditions